Qiagen leaps across Atlantic to buy synthetic DNA maker; push into U.S. continues with $110 million stock swap

Article Abstract:

The article focuses on Qiagen N.V.'s agreement to purchase Operon Technologies Inc. in a stock swap valued at $110 million (Euro115.4 million). Privately held Operon will be the largest purchase yet for Qiagen, a biotech firm.

United States, Brief Article, Operon Technologies Inc.

---

Shire to Purchase BioChem of Canada In Stock Agreement

Article Abstract:

Shire Pharmaceuticals Group PLC will acquire BioChem Pharma Inc. for $4 billion in Shire stock.

United Kingdom, Canada, Shire Pharmaceuticals Group PLC, Shire BioChem Inc., BCHE

---

Qiagen acquires Sawady of Japan in stock deal

Article Abstract:

Qiagen NV has purchased Japan-based Sawady group for approximately $18 million (20.1 million euros). Sawady is Japan's second-largest synthetic nucleic acid supplier.

Japan, Nucleic Acids, Sawady

Similar abstracts:

• Abstracts: Phillips is close to acquiring Tosco for $7 billion in stock. Occidental is set to acquire Altura for $3.5 billion
• Abstracts: Spain's Santander, Abbey National of U.K. poised for $15 billion deal . Standard Chartered bids to buy Grindlays for $1.6 billion
• Abstracts: Nortel negotiates to buy Swiss plant from JDS for $3 billion in stock. Nortel Networks will acquire Xros in stock deal
• Abstracts: ABN Amro sues APP, three units to recover $31 million in debt. World Online shareholders look to Sue Brink, ABN Amro
• Abstracts: SAirGroup to sell Swissotel to Raffles for 340 million euros. SAirGroup agrees to buy control of Sabena in share-swap deal

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.